We are live on ! Find out more
TLX

Telix Pharmaceuticals
TLX

1 hedge funds and large institutions have $57.4K invested in Telix Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
1
Holders Change
+1
Holders Change %
–
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$58.6K

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
UBS Group
1
UBS Group
Switzerland
$57.4K +$58.6K +3,730 New

TLX Hedge Fund Activity: Q4 2024 in Review

1 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in Telix Pharmaceuticals (TLX) for Q4 2024, worth a combined $57.4K.

Buyers outnumbered sellers: 1 fund opened new TLX positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, opening a new position worth an estimated $58.6K.

  • 1 institutional investor held Telix Pharmaceuticals (TLX) as of Q4 2024, up from 0 in Q3 2024.
  • Funds reported $57.4K of Telix Pharmaceuticals stock for Q4 2024.
  • 1 fund opened new Telix Pharmaceuticals positions in Q4 2024 and 0 closed out, a net change of +1 holder.
  • The largest Telix Pharmaceuticals buyer in Q4 2024 was UBS Group, an estimated $58.6K added.

Based on aggregated 13F filings for Q4 2024.